Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
Written by Robert Izquierdo for The Motley Fool -> Christian Heidbreder sold 18,586 shares for a transaction value of approximately ~$707,000 on June 11, 2026. This represents 7.54% of Heidbreder's direct holdings at the time of the transaction, reducing his position from 246,5
Christian Heidbreder sold 18,586 shares for a transaction value of approximately ~$707,000 on June 11, 2026.
This represents 7.54% of Heidbreder's direct holdings at the time of the transaction, reducing his position from 246,509 to 227,923 shares.
All shares sold were held directly; there were no indirect or derivative securities involved.
On June 11, 2026, Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals (NASDAQ:INDV) , reported the sale of 18,586 shares of common stock in an open-market transaction, as detailed in the SEC Form 4 filing .
Transaction value based on SEC Form 4 reported price ($38.06); post-transaction value based on June 11, 2026 market close ($38.13).
* 1-year performance calculated using June 11, 2026 as the reference date.
Indivior is a specialty pharmaceutical company with a focus on opioid dependence therapies, leveraging a portfolio of branded products and a global commercial footprint.
The company’s strategy centers on research-driven product development and targeted market expansion in addiction treatment. Its competitive edge stems from its established expertise in buprenorphine formulations and its ability to address a critical public health need.
